Based on a systematic review of the performance of eGFR equations in patients with cancer, the American Society of Onco-Nephrology issued a position statement in 2024 advocating the use of eGFR equations incorporating both creatinine and cystatin C in patients with cancer [14]. The gene discussed is CST3; the disease is cancer.